M&A - NorthView Acquisition Corp

Back to List of Mergers and Acquisitions

Form Type: 10-K

Filing Date: 2025-03-31

Corporate Action: Merger

Type: Update

Accession Number: 000101376225004396

Filing Summary: NorthView Acquisition Corp was formed as a blank check company to pursue business combinations, particularly in the healthcare sector, focusing on small cap companies. In a significant development, on November 7, 2022, the company entered into a Merger Agreement with Profusa, Inc., aiming to bring Profusa into the NorthView structure. The merger will see Profusa become a wholly-owned subsidiary, fundamentally rebranding NorthView as Profusa, Inc. This business combination has various cash and equity-based compensations linked to performance milestones, including specific revenue targets for fiscal years 2024 and 2025. The agreement has undergone multiple amendments to adjust financial milestones and deadlines, including a recent extension that pushes the deadline for completing the merger to June 22, 2025. As of March 21, 2025, shareholders approved this extension, allowing NorthView to prolong its efforts to complete the business combination. Additionally, NorthView is facing operational changes due to its delisting from Nasdaq and transitioning to OTC Pink, but still aims to significantly enhance its market position through the merger with Profusa.

Document Link: View Document

Additional details:

Business Combination Date: 2024-06-22


Total Equity Value: 155000000


Earnout Shares Possible: 3875000


Milestone Event 2024 Revenue: 11864000


Milestone Event 2025 Revenue: 99702000


Trust Account Funds As Of Dec 31 2024: 8300000


Public Shares Redeemed: 532958


Trust Account Funds After Extension: 1900000


Form Type: DEF 14A

Filing Date: 2025-03-07

Corporate Action: Merger

Type: Update

Accession Number: 000121390025021270

Filing Summary: NorthView Acquisition Corp is holding a special meeting of stockholders on March 18, 2025, primarily to consider and vote on several proposals regarding the extension of the deadline for completing a business combination with Profusa, Inc. The meeting will occur virtually, allowing stockholders to participate from any location. Key proposals include extending the deadline for consummating a business combination from March 22, 2025, to June 22, 2025, and making various amendments to the company's charter and trust agreement to facilitate this extension. The Board of Directors believes that obtaining this additional time is in the best interests of stockholders to allow completion of the proposed merger. If stockholders do not approve these proposals and a business combination is not completed by the March deadline, the company will dissolve and liquidate its assets. Stockholders will also have redemption rights to receive cash for their shares, with a projected per-share redemption price around $12.19 based on current trust account balances. The proposals are detailed in the proxy statement included with the notice of the meeting. Voting is crucial as failure to vote could be treated as a vote against the proposals. The document also outlines the procedural aspects of the meeting and redemption rights for stockholders with public shares.

Document Link: View Document

Additional details:

Proposal Name: Extension Proposal

Description: Amendment to extend the deadline for business combination from March 22, 2025, to June 22, 2025, to allow more time for a merger.


Proposal Name: Trust Amendment Proposal

Description: Amendment to the Investment Management Trust Agreement to authorize the extension and its implementation.


Proposal Name: NTA Amendment Proposal

Description: Amendment to eliminate limitation on redeeming public shares if net tangible assets exceed $5,000,001.


Proposal Name: Adjournment Proposal

Description: Proposal to adjourn the meeting to a later date if necessary to facilitate solicitation of proxies.


Redemption Price: 12.19

Redemption Date: March 14, 2025

Special Meeting Date: 2025-03-18


Form Type: 425

Filing Date: 2025-02-19

Corporate Action: Merger

Type: Update

Accession Number: 000121390025014988

Filing Summary: On February 11, 2025, NorthView Acquisition Corp. entered into Amendment No. 4 to the Merger Agreement with Profusa, Inc. The amendment revises the Company Reference Value and extends the deadline for Profusa to consummate the APAC Joint Venture until December 31, 2025. Additionally, it alters the earnout revenue target for fiscal year 2026 to $11,864,000 from a previous target of $99,702,000 for 2025. This report also details a Securities Purchase Agreement with an institutional investor for senior secured convertible promissory notes totaling up to $22,222,222, structured in tranches, with specific conditions for additional note purchases based on trading volumes and other criteria.

Document Link: View Document

Additional details:

Company Reference Value: updated Company Reference Value in the Merger Agreement


Milestone Event Iii Deadline: December 31, 2025


Milestone Event Iv Target: $11,864,000 for fiscal year 2026


Total Amount Of Convertible Notes: $22,222,222


Initial Closing Amount: $9,000,000


Initial Notes Amount: $10,000,000


Second Purchase Amount: $2,222,222


Second Purchase Price: $2,000,000


Third Purchase Amount: $5,555,555


Third Purchase Price: $5,000,000


Lock Up Agreement Terms: Common stock holders agree to restrictions until termination of Lock-Up Agreement.


Form Type: 8-K

Filing Date: 2025-02-19

Corporate Action: Merger

Type: Update

Accession Number: 000121390025014987

Filing Summary: NorthView Acquisition Corp. entered into Amendment No. 4 to a previously disclosed Merger Agreement with Profusa, Inc. on February 11, 2025. The amendment revises the Company Reference Value due to financing proceeds received by Profusa, extends the deadline for Profusa to complete the APAC Joint Venture from December 31, 2024 to December 31, 2025, and modifies the earnout revenue target for fiscal year 2026 from $99,702,000 to $11,864,000. Additionally, NorthView has entered into a Securities Purchase Agreement with an institutional investor for the purchase of up to $22,222,222 in senior secured convertible promissory notes, with an initial closing amount of $9,000,000 aligned with the Business Combination's consummation. The agreement outlines multiple purchase tranches conditioned on certain performance and registration criteria. Each note matures 18 months from the closing date and is convertible under specified conditions. A Lock-Up Agreement will restrict certain holders from selling their shares for a defined period post-initial closing.

Document Link: View Document

Additional details:

Item 1: Amendment to Merger Agreement


Item 2: Securities Purchase Agreement


Item 3: $22,222,222 in Convertible Notes


Item 4: Initial closing amount of $9,000,000


Form Type: S-4/A

Filing Date: 2025-02-12

Corporate Action: Merger

Type: Update

Accession Number: 000121390025012354

Filing Summary: This document is an amendment to the Registration Statement under the Securities Act of 1933 filed by NorthView Acquisition Corporation pertaining to a business combination proposal with Profusa, Inc. The amendment discusses various aspects of a merger agreement originally dated November 7, 2022, which has undergone several amendments. The document outlines details concerning the special meeting of stockholders to approve the merger and related proposals including changes to the Certificate of Incorporation, governance provisions, issuance of new common stock, and election of directors for New Profusa. Stakeholders are urged to vote on several key proposals that are interdependent for the consummation of the merger. Post-merger, NorthView will be renamed Profusa, Inc., and its securities will be listed on Nasdaq. The document also mentions potential conflicts of interest, redemption rights for public stockholders, and financial arrangements related to the merger, including Sponsor loans.

Document Link: View Document

Additional details:

Approximate Date Of Commencement: As soon as practicable after this Registration Statement becomes effective.

Equity Value: 155000000

Incentive Equity Value: 29018330

Private Placement Value: 13654216

Aggregate Exercise Price: *Value not specified*

Aggregate Company Incentive Amount: *Value not specified*

Exchange Ratio: *Value not specified before closing*

Per Share Merger Consideration: *Value not specified before closing*

Redemption Price Estimate: 11.84

Sponsor Lending Estimate: 1900000

Founder Shares Owned: 4743750

Private Placement Warrants Owned: 5162500

Conversion Price Of Loans: 2.22


Comments

No comments yet. Be the first to comment!